| Title: | Lipid-lowering drug and complement factor H genotyping-personalized treatment strategy for age-related macular degeneration |
| Journal: | iScience |
| Published: | 8 Nov 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39640589/ |
| DOI: | https://doi.org/10.1016/j.isci.2024.111344 |
Publication 14162
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
We investigated whether the effect of lipid-lowering drugs (LLDs) on age-related macular degeneration (AMD) differs according to the main complement genetic variants in Singapore Epidemiology of Eye Diseases (SEED) (n = 5,579) and UK Biobank studies (n = 445,727). The effect of LLD was determined for each stratum of 20 complement genetic variants. In SEED, 484 individuals developed AMD and 216 showed progression over 6 years. In the UK Biobank, 913 participants developed AMD over 11 years. rs1061170 variant (complement factor H gene) was the only variant for which we found a protective effect in both populations. This effect was found in individuals carrying at least one C allele in SEED (odds ratio [OR] = 0.41; 95% confidence interval [CI], 0.19-0.87) and in individuals carrying two C alleles in UK Biobank (hazard ratio [HR] = 0.65; 95% CI, 0.45-0.93). These effects corresponded to a 50% and 35% decrease in AMD risk, respectively. Our study highlights the potential for personalized therapy for AMD based on complement genotyping.</p>
14 Authors
- Can Can Xue
- Kelvin Y.C. Teo
- Yih Chung Tham
- Hengtong Li
- Sahil Thakur
- Charumathi Sabanayagam
- Qiao Fan
- David L. Silver
- Xiaomeng Wang
- Chui Ming Gemmy Cheung
- Tien Yin Wong
- Usha Chakravarthy
- Ching-Yu Cheng
- Simon Nusinovici
1 Application
| Application ID | Title |
|---|---|
| 45925 | Risk Factors, Biomarkers and Impact of Major Vision-Threatening Eye Diseases |
Enabling scientific discoveries that improve human health